It will certainly be more in-depth and more detailed. Right now there is technical information and numbers--i.e., the percentage of patients who respond to a certain therapy, any changes in morbidity, mortality, in percentages--but it's more like an abstract of the study. In future there will be much more detail provided.
As well, the information is presented right now in quite a technical format. It's written for the drug plans and for health care professionals. Again, in the coming year we'll be making available lay versions of those reasons for recommendations.